Clinical Trials Browser

Phase 2 × INDUSTRY × vactosertib × Clear all

NCT04515979 2024-12-09

Vactosertib in Combination with Pembrolizumab for PD-L1 Positive Non-small Cell Lung Cancer (NSCLC) Subjects

Phase 2 Terminated

Carcinoma, Non-Small-Cell Lung